表紙
市場調查報告書
商品編碼
1075356

全球疫苗市場:增長機會

Global Vaccine Growth Opportunities

出版日期: | 出版商: Frost & Sullivan | 英文 88 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

受持續大流行的啟發,疫苗開發商正在加快變革步伐,使製造多樣化和供應鏈數字化,重點是擴大外包。

製造商採用創新技術和供應鏈彈性來提高其在全球疫苗市場的戰略地位,同時確保疫苗在需求未得到滿足的國家的有效供應。您所做的是一種非凡的新商業模式。

本報告對全球疫苗市場進行研究和分析,並提供有關戰略要求、增長機會分析、增長環境和知名公司的信息。

目錄

戰略要求

  • 為什麼增長變得越來越困難?
  • 戰略要點 8 (TM)
  • 全球疫苗行業三大戰略要素
  • 增長機會推動增長管道引擎 (TM)
  • 疫苗狀態-要點
  • 增長機會矩陣

增長機會分析:疫苗

  • 分析範圍
  • 疫苗-介紹與細分
  • 定義-按生產系統
  • 定義-按技術類型
  • 推動疫苗市場增長的因素
  • 制約疫苗市場增長的因素

成長環境

  • 疫苗接種率
  • 未滿足疫苗需求的地區
  • 疫苗行業的政府舉措:2021 年
  • 疫苗開發商情況
  • 管道快照:COVID-19 疫苗
  • 管道快照:疫苗(2021 年)
  • 疫苗供應鏈-關鍵利益相關者
  • 疫苗價值鏈——各利益相關方的作用不斷擴大
  • 疫苗分發框架
  • 疫苗分發場景
  • 不斷發展的疫苗交付模式——加強私營公司的分銷
  • 數字技術在疫苗供應鏈中的作用越來越大
  • 主要夥伴關係與合作:常規疫苗(2020-2022 年)
  • 主要夥伴關係和合作:COVID-19 疫苗(2020-2022 年)
  • 與 Bio-CDMO 就已獲批准的 COVID-19 疫苗建立主要製造合作夥伴關係 - 美國
  • 與 Bio-CDMO 就獲批的 COVID-19 疫苗建立主要製造合作夥伴關係 - 歐洲
  • 疫苗產業關鍵戰略
  • 疫苗行業的技術進步

增長機會分析:常規疫苗

  • 常規疫苗的關鍵增長指標
  • 調查方法
  • 預測的先決條件
  • 收入預測
  • 收入預測分析
  • 收入預測:按技術類型
  • 回報率預測:按技術類型
  • 收入:按生產系統
  • 回報率:按地區
  • 競爭環境
  • 市場份額分析

增長機會分析:COVID-19 疫苗

  • 主要增長指標
  • 調查方法
  • 預測的先決條件
  • 收入預測
  • 收入預測分析
  • 收入:按技術類型
  • 收入:按生產系統
  • 回報率:按地區
  • 競爭環境
  • 市場份額分析

著名公司

  • 知名公司 (2022-2027)

增長機會宇宙:疫苗

  • 增長機會 1- 建立開發基於核酸的癌症和 HIV 疫苗的能力
  • 有希望的主要核酸疫苗正在研發中
  • 生長機會 2 兒科聯合疫苗,適用於非常廣泛的感染
  • 聯合疫苗的緩解措施
  • 增長機會 3-新興經濟體的技術轉讓以提高生產效率和速度
  • 增長機會 4-發展中國家通過許可和合資建立國內能力
  • 增長機會5-開發新的疾病領域以滿足不斷增長的疫苗接種需求

下一步

目錄
Product Code: PCCF-52

Capability Expansion in Nucleic Acid-based Vaccines is Accelerating the Disruption in Vaccines Globally

Frost & Sullivan provides an outlook for the global vaccine industry for 2022 and beyond, including emerging trends and growth opportunities. Innovation, which remains mainstream in vaccine development, is augmenting investments by emerging vaccine developers in designing novel technology platforms, especially for nucleic acid-based vaccines. Spurred by the ongoing pandemic, vaccine developers have accelerated the pace of transformation, and the concepts of manufacturing decentralization, digitization of supply-chain, and increased outsourcing have taken center stage. Moreover, companies entering into public-private-partnerships to capitalize on the current situation are likely to establish synergistic relationships at all levels.

The new vision in 2022 is focused on government authorities having several shifts in vaccine development programs and reaching "zero-dose" children to attain vaccination equity in emerging economies. The tailored and targeted approach used by logistics companies for individual vaccines is providing catalytic support to vendors in the vaccine industry. The adoption of innovative technologies and supply-chain resilience by manufacturers to improve their strategic position in the global vaccine market, while ensuring the accessibility of vaccines remains outcome-based in countries with unmet needs, is a prominently emerging business model. The rising focus on prophylactic management of COVID-19 in 2021-2022 is anticipated to shift toward novel delivery modes of traditional vaccines and on highly prevalent disease areas, such as RSV, HIV, and cancer. Technology transfer is crucial for outsourcing to CDMOs, and the shift toward the development of patient-centric models for vaccine delivery is paramount.

Research Highlights:

  • Traditional and COVID-19 vaccine market size, including key segments from 2022 to 2027
  • Dynamics around COVID-19 vaccination and the path to endemicity
  • Role of advancements, such as decentralization, technologies, and new modalities, in driving the vaccine value-chain transformation
  • The current and future R&D and investment outlook, and its evolution
  • Strategic time-defined growth opportunities for ecosystem participants to focus on in the near future

Table of Contents

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • Top Three Strategic Imperatives in the Global Vaccines Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™
  • Vaccine Landscape-Key Takeaways
  • Growth Opportunity Matrix

Growth Opportunity Analysis, Vaccines

  • Scope of Analysis
  • Vaccines-Introduction and Segmentation
  • Definitions-By Production System
  • Definitions-By Technology Type
  • Definitions-By Technology Type (continued)
  • Growth Drivers for Vaccines Market
  • Growth Restraints for Vaccines Market

Growth Environment

  • Vaccine Coverage Rate
  • Areas of Unmet Vaccine Needs
  • Government Initiatives in Vaccines Industry, 2021
  • Vaccine Developers Landscape
  • Pipeline Snapshot, COVID-19 Vaccines
  • Pipeline Snapshot, Vaccines, 2021
  • Vaccines Supply Chain-Key Stakeholders
  • Vaccines Value Chain-The Expanding Role of Different Stakeholders
  • Vaccines Distribution Framework
  • Vaccines Distribution Scenario
  • Evolving Vaccine Delivery Model-Private Sector Fortifying Distribution
  • Increasing Role of Digital Technology in Vaccines Supply Chain
  • Key Partnerships and Collaborations, Traditional Vaccines, 2020-2022
  • Key Partnerships and Collaborations, COVID-19 Vaccines, 2020-2022
  • Key Partnerships and Collaborations, COVID-19 Vaccines, 2020-2022 (continued)
  • Key Manufacturing Partnerships With Bio-CDMOs for Approved COVID-19 Vaccines-US
  • Key Manufacturing Partnerships With Bio-CDMOs for Approved COVID-19 Vaccines-Europe
  • Key Strategies in the Vaccine Industry
  • Technological Advancements in Vaccines Industry

Growth Opportunity Analysis, Traditional Vaccines

  • Key Growth Metrics for Traditional Vaccines
  • Research Methodology
  • Forecast Assumptions
  • Revenue Forecast
  • Revenue Forecast Analysis
  • Revenue Forecast by Technology Type
  • Percent Revenue Forecast by Technology Type
  • Revenue by Production System
  • Percent Revenue by Region
  • Competitive Environment
  • Market Share Analysis

Growth Opportunity Analysis, COVID-19 Vaccines

  • Key Growth Metrics
  • Research Methodology
  • Forecast Assumptions
  • Revenue Forecast
  • Revenue Forecast Analysis
  • Revenue by Technology Type
  • Revenue by Production System
  • Percent Revenue by Region
  • Competitive Environment
  • Market Share Analysis

Companies to Watch

  • Companies to Watch From 2022-2027
  • Companies to Watch From 2022-2027 (continued)

Growth Opportunity Universe, Vaccines

  • Growth Opportunity 1-Building Capabilities for the Development of Nucleic Acid-based Vaccines for Cancer and HIV
  • Growth Opportunity 1-Building Capabilities for the Development of Nucleic Acid-based Vaccines for Cancer and HIV (continued)
  • Promising Key Nucleic Acid-based Vaccines in the Pipeline
  • Growth Opportunity 2-Pediatric Combination Vaccines for Highly Prevalent Infectious Diseases
  • Growth Opportunity 2-Pediatric Combination Vaccines for Highly Prevalent Infectious Diseases (continued)
  • Mitigation Measures for Combination Vaccines
  • Growth Opportunity 3-Tech Transfer in Emerging Economies to Boost the Production Efficiency and Pace
  • Growth Opportunity 3-Tech Transfer in Emerging Economies to Boost the Production Efficiency and Pace (continued)
  • Growth Opportunity 4-Developing Countries Entering Into Licensing and Joint Ventures to Build Domestic Capabilities
  • Growth Opportunity 4-Developing Countries Entering into Licensing and Joint Ventures to Build Domestic Capabilities (continued)
  • Growth Opportunity 5-Exploring New Disease Areas to Meet the Growing Need for Immunization
  • Growth Opportunity 5-Exploring New Disease Areas to Meet the Growing Need for Immunization (continued)
  • Growth Opportunity 5-Exploring New Disease Areas to Meet the Growing Need for Immunization (continued)

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • List of Exhibits (continued)
  • List of Exhibits (continued)
  • Legal Disclaimer